En desarrollo
Business·ayerResumen IA
Eli Lilly Acquires AtaiBeckley, Signaling Big Pharma's Embrace of Psychedelic Drugs
Eli Lilly is acquiring psychedelic drug maker AtaiBeckley for up to $3.8 billion, indicating Big Pharma's growing interest in these treatments for mental health. This follows positive clinical trial results and a Trump executive order to fast-track FDA reviews, despite past regulatory hurdles.
C
CNBC World7 min de lectura